The Role of Inflammation in Parkinson’s disease

New research has expanded our understanding of the potential role of inflammation in the progression of Parkinson’s disease.

What is inflammation?

The immune system is responsible for protecting the body from foreign substances such as infections or toxins. Inflammation is the immune system’s response when a foreign substance is detected. This response consists of a cascade of cellular events that produces a hostile environment for the intruders, allowing the body to defend itself. The human body needs inflammation when it is under attack, but at times the cascade that is set in motion can causes damage to healthy tissue. This is the general understanding of what goes wrong in autoimmune diseases such as Lupus or rheumatoid arthritis. Medications that suppress the immune system are therefore used to treat this type of disease.

The brain and the body

Many organs, including the brain, have their own system in place to counter any infection or toxic substance that might be present. Past thinking was that the immune system of the body and the immune system of the brain did not influence each other due to natural barriers that prevented crosstalk. These barriers do in fact exist, but it is now understood that:

  1. These barriers may be compromised in brain diseases such as Parkinson’s disease (PD).
  2. Despite these barriers, there is indeed communication between the two immune systems and the inflammatory response that takes place in the body can exert its influence on the brain as well.

Parkinson’s disease and inflammation

For more than thirty years it has been understood that inflammatory changes occur in the brains of patients with PD, but only in the last few years has inflammation been viewed as part of the cause of the progressive nature of the disease and not just a result of the disease. What this means, is that the disease may start because of abnormal accumulation of the protein alpha-synuclein into clumps known as Lewy bodies, but this abnormal accumulation may be triggering the body’s inflammatory response, which then causes the damage and further disease progression.

Dr. David Standaert, the Chairman of APDA’s Scientific Advisory Board, and director of the APDA Center for Advanced Research at the University of Alabama, is an expert on inflammation and Parkinson’s disease and has summarized for the scientific community how alpha-synuclein triggers inflammation in PD.

Why is it important to understand inflammation in PD?

What is exciting about this new understanding is that it opens up a whole array of potential treatment options.

  • Maybe we don’t have to stop the alpha-synuclein from accumulating if we can stop the immune response that is triggered.
  • There are drugs already in clinical use that control the immune response.

Research on the link between inflammation and PD

On May 31, 2018, an article was published in the Annals of Clinical and Translational Neurology  which supports this possible path to treatment of PD. Dr. Brad Racette, the lead author on the article, is a researcher at Washington University School of Medicine, which is an APDA Center for Advanced Research. His work is directly supported by the APDA Greater St. Louis Chapter. He and his team analyzed Medicare data and selected all the newly-diagnosed patients in the year 2009 and a randomly selected group of controls without PD. They then identified whether the patients in the two groups were ever prescribed any of seven classes of immunosuppressant drugs, medications that decrease the ability of the body to mount the immune response. Prescriptions up to a year prior to diagnosis were analyzed.

What did the study find?

People who were prescribed two of the classes of immunosuppressant medications had lower risks of developing PD. These two classes were corticosteroids and inosine monophosphate dehydrogenase (IMDH) inhibitors (a class which includes azathioprine, leflunomide, and mycophenolate).
The authors highlight a number of limitations of the study (summarized below) that need to be considered, and that for the moment at least, will keep clinicians from prescribing these medications to everyone who has PD.

    1. Immunosuppressant medications in general tamp down the immune system that fights infection, leaving people who are on these medications more prone to infection.
    2. Corticosteroids specifically have a whole array of additional side effects including behavioral changes and bone loss that make them unsuitable for many people with PD.
    3. It is important to emphasize that taking these medications is associated with a lower risk of PD and does not necessarily cause the lower risk of PD. There could be another reason why taking these medications and a lower risk of PD coexist in the same patients. For example, the database that was analyzed did not capture whether patients smoked. This omission is important because smokers tend to have lower rates of PD (a subject I will explore in a future blog) and also tend to take corticosteroids for pulmonary disease. Therefore, it is possible that the lower rate of PD in those who take corticosteroids can be explained by the smoking variable.

Despite these caveats, the results are intriguing and certainly continue to highlight the potential role that inflammation plays in the development of PD.

Inflammation and the gut in PD

The role of inflammation in PD is wide-reaching and leads us to another very hot topic in the field of PD research which is the role of inflammation specifically in the gut of patients with PD. We will elaborate further upon this topic in a future blog dedicated to the gastrointestinal tract and PD, so stay tuned.

The microbiome as source of inflammation

The human gut harbors trillions of micro-organisms referred to collectively as the microbiome. Current understanding is that the microbiome provides a number of benefits to the human including: help with digestion of food, help with warding off harmful microorganisms, and creation of needed vitamins. The microbiome varies from person to person and is influenced by many factors including diet. Although no two microbiomes are identical, people with certain diseases may share similarities in their microbiomes. Along these lines, the microbiome in PD patients appears to be somewhat different as compared to non-PD patients. This observation has led to the theory that the changes in the bacterial composition in the gut of people with PD may trigger increased inflammation in the gut which fuels the disease.

Parkinson’s and inflammatory bowel disease (IBD)

As stated above, increased inflammation in the gut may contribute to disease development in PD. This may help explain why patients with Inflammatory bowel disease (IBD), a condition in which over-activation of the immune system causes gut dysfunction, have an increased risk of PD. Recent research has demonstrated that certain genetic variants of Leucine rich repeat kinase 2 (LRRK2), a risk factor for PD, is also a risk factor for IBD. Another recent study, which is similar to Dr. Racette’s study, showed that taking medications that decrease the immune response to treat IBD, lowers the risk of developing PD.

Tips and take-aways

      • Inflammation both in the gut and the brain likely contribute to development of PD.
      • Additional research must be done before any immunosuppressant medications can safely be prescribed as part of a treatment plan for PD.
      • Stay tuned for clinical trials that investigate ways in which controlling the immune system can help protect against PD.

Share this page:

Do you have a question or issue that you would like Dr. Gilbert to explore? Suggest a Topic

Dr. Rebecca Gilbert

APDA Vice President and Chief Scientific Officer

Dr. Gilbert received her MD degree at Weill Medical College of Cornell University in New York and her PhD in Cell Biology and Genetics at the Weill Graduate School of Medical Sciences. She then pursued Neurology Residency training as well as Movement Disorders Fellowship training at Columbia Presbyterian Medical Center. Prior to coming to APDA, she was an Associate Professor of Neurology at NYU Langone Medical Center. In this role, she saw movement disorder patients, initiated and directed the NYU Movement Disorders Fellowship, participated in clinical trials and other research initiatives for PD and lectured widely on the disease.

A Closer Look ArticlePosted in Parkinson's Research

DISCLAIMER: Any medical information disseminated via this blog is solely for the purpose of providing information to the audience, and is not intended as medical advice. Our healthcare professionals cannot recommend treatment or make diagnoses, but can respond to general questions. We encourage you to direct any specific questions to your personal healthcare providers.